Collectively, this study identifies XAF1 as a novel antagonist of TRIM28 and the presence of mutual antagonism between XAF1 and TRIM28, raising the possibility that the restoration of balanced XAF1-TRIM28 interplay could be an attractive avenue for the therapeutic intervention of tumor progression. Here, TRIM28 is linked to neoplasm.